Vaxine is an Australian vaccine biotechnology company first established in 2002, that focusses on development of innovative vaccines against a wide range of infectious and chronic diseases. Vaxine has subsidiaries in Japan and the USA in addition to over 50 research partnerships and collaborations around the globe.

Vaxine's lead products include  vaccines against seasonal and pandemic influenza, Japanese encephalitis, West Nile virus, hepatitis, malaria, rabies, and allergy. With funding from the US National Institutes of Health, Vaxine has developed the Advax™ range of polysaccharide vaccine adjuvants, representing a major breakthrough in safe and effective adjuvants for both adult and pediatric use.Vaxine also has a veterinary division that is commercialising vaccines and vaccine adjuvants tailored to specific animal health problems.

In July 2009, Vaxine undertook a world-first clinical trial in Adelaide of the first successful recombinant H1N1 2009 (swine flu) vaccine. This trial not only confirmed the ability of Advax™ adjuvant technology to dramatically enhance the effectiveness of pandemic influenza vaccines, but also proved the superiority of a recombinant vaccine approach over traditional egg-based pandemic influenza vaccines. This landmark clinical trial has further cemented Advax™ adjuvant technology as the lead future vaccine adjuvant, a fact recognised by the multitude of prizes and awards won by Vaxine since the completion of this clinical trial.

In exciting news, Vaxine has just won yet another industry award, namely the prestigious Vaccine Industry Excellence (VIE) Award for the Most Innovative Asian Biotech. Presented at the 2011 World Vaccine Congress Asia – just completed in Singapore, the awards recognize and celebrate the leaders, innovators and pioneers in the Asian vaccines industry. Fellow Australian biotech Ondek Pty Ltd headed by Nobel Laureate Professor Barry Marshall also won the award for most Successful Therapeutic Vaccine Development at the awards.Previously a finalist in these awards, this is the first time that Vaxine has won a VIE award.

This follows on  Vaxine being awarded the 2011 Biospectrum Editor's Choice Award for Emerging Company of the Year, an award made at the Biospectrum Annual Industry Awards held in conjunction with the 3rd Biospectrum Asia Pacific Conference in Singapore in March 2011.